Your browser doesn't support javascript.
loading
Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice.
Kiesewetter, B; Mazal, P; Kretschmer-Chott, E; Mayerhoefer, M E; Raderer, M.
Affiliation
  • Kiesewetter B; Departments of Medicine I, Division of Oncology.
  • Mazal P; Departments of Pathology.
  • Kretschmer-Chott E; Departments of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
  • Mayerhoefer ME; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Biomedical Imaging and Image-guided Therapy, Division of General and Paediatric Radiology, Medical University of Vienna, Vienna, Austria.
  • Raderer M; Departments of Medicine I, Division of Oncology. Electronic address: markus.raderer@meduniwien.ac.at.
ESMO Open ; 7(3): 100478, 2022 06.
Article in En | MEDLINE | ID: mdl-35525183
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Somatostatin / Neuroendocrine Tumors Type of study: Guideline / Observational_studies Limits: Humans Language: En Journal: ESMO Open Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Somatostatin / Neuroendocrine Tumors Type of study: Guideline / Observational_studies Limits: Humans Language: En Journal: ESMO Open Year: 2022 Document type: Article